ISN-ACT Trial List: September 2018
ISN Academy. ISN-ACT . Sep 3, 2018; 227642 Topic: General Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Description
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed. This month, we reviewed the following trials:

- Iron-based binder may lower FGF-23 levels
Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoeitin Responsiveness in Hemodialysis Patients
Maruyama, et al. Am J Nephrol. 2018;47(6):406-414

- Effect of Electronic Health Record–Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management: A Randomized Clinical Trial
Persell, et al. JAMA Intern Med. 2018;178(8):1069–1077

- Bicarbonate therapy may preserve renal function and muscle mass
Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial
Dubey, et al. Nephrol Dial Transplant. 2018 Jul 24. doi: 10.1093/ndt/gfy214

- Lower doses of mycophenolate may be effective in lupus nephritis
Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
Sedhain et al. BMC Nephrology. 2018;19:175

- Electronic record based identification of CKD patients and associated treatment targets can boost adherence to recommended therapies
Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial
Tuot, et al. Am J Kidney Dis. 2018;72(2):168-177

- Patient self-management program reduces sodium intake in hemodialysis patients
Effectiveness of self-management support in maintenance haemodialysis patients with hypertension: A pilot cluster randomized controlled trial
Huang, et al. Nephrology. 2018;23(8):755-763




 

A preview of this infographic is available below, and can be downloaded to the left.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies